View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, May 5 (HealthDay News) -- Although researchers have obtained important information about the natural history and clinical management of 2009 H1N1 virus infection, considerable research gaps remain, according to a review published in the May 6 issue of the New England Journal of Medicine.
The Writing Committee of the World Health Organization Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza reviewed virologic, epidemiologic, and clinical data on 2009 H1N1 infections, and summarized significant issues for clinicians around the world.
The committee confirmed that the virus is susceptible to the neuraminidase inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza) but is usually resistant to amantadine and rimantadine, and that therapy with a neuraminidase inhibitor is especially important for patients with underlying risk factors (such as pregnancy) and severe or progressive clinical illness. However, they identified major gaps in the understanding of viral transmission, disease pathogenesis, genetic and other host factors that have a role in susceptibility or disease severity, as well as ideal management of severe illness.
"Available findings highlight the importance of early use of antiviral drugs and antibiotics in the treatment of serious cases and of the potential value of influenza-specific and pneumococcal vaccines for prevention. Both the gaps in knowledge and the experience to date underline the urgent need for better international collaboration in clinical research, particularly in the case of diseases with pandemic potential, for which rapid detection, investigation, and characterization of clinical syndromes are prerequisites for improved mitigation of their public health consequences," the authors write.
One committee member disclosed a financial relationship with Roche related to studies of oseltamivir, and another member disclosed financial relationships with Baxter, Novartis, and GlaxoSmithKline.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top